Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

作者
Peter Borchmann,Tom van Meerten,Pierre Bories,Peter Dreger,Laszlo Gopsca,Pim G. N. J. Mutsaers,Matthias Edinger,Arpád Illés,Bastian von Tresckow,Peter Neumeister,Normann Steiner,Ulrich Jaeger,Ana Triguero Moreno,Laimonas Griškevičius,Gloria Iacoboni,François Lemonnier,Jaap A. van Doesum,Nirav Niranjan Shah,Rimas J. Orentas,Stefan Miltenyi
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 669-669 被引量:5
标识
DOI:10.1182/blood-2025-669
摘要

Abstract Background: Zamtocabtagene autoleucel (zamto-cel) is an autologous, non-cryopreserved tandem CD20-CD19 directed CAR-T cell therapy produced on the fully automated CliniMACS® Prodigy System in 12 days. Interim results from a phase II study (NCT04792489) in adults with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after at least 2 lines of treatment had shown a promising risk-benefit profile. Here, we report the results of the primary analysis of the pivotal DALY 2-EU trial (NCT04844866), which compares zamto-cel with standard of care (SoC) as second-line (2L) therapy for r/r LBCL in non-transplant eligible (NTE) patients (pts). Methods: DALY 2-EU is a randomized, multicenter, pivotal study. Adult NTE pts with primary refractory or relapsed (≤24 months after start of first-line [1L] therapy) LBCL were randomly assigned to receive zamto-cel or SoC (R-GemOx, n=78 or Pola-BR, n=8). The primary analysis was the comparison of zamto-cel vs R-GemOx. Key inclusion criteria were LBCL, ECOG PS ≤ 2, age ≥ 18 years (y) and one NTE criterion, age ≥ 65 y and impaired organ function or age ≥70 y. Pts in the zamto-cel arm started lymphodepletion (fludarabine and cyclophosphamide) during manufacturing, followed by infusion of a non-cryopreserved zamto-cel product, target dose 2.5 × 106 CAR-T cells/kg body weight. No chemoimmunotherapy bridging except steroids was allowed. One-sided crossover to zamto-cel was implemented during the trial. The primary endpoint was event free survival (EFS), defined as the time between the date of randomization and the date of objective disease progression, failure to achieve at least partial response at or beyond week 8 leading to a new anti-lymphoma therapy, or death of any cause, whichever occurred first.The significance level of the 1-sided stratified log rank test assessing for superiority is ≤ 0.025. The disease was assessed by a blinded, independent review committee using the Lugano criteria 2014. Key secondary endpoints included remission rates, progression-free survival (PFS), and overall survival. The efficacy analyses were conducted on the intention-to-treat (ITT) set. Results: Between 10/2021 and 07/2024, 168 pts were randomized in 12 countries (N=82 zamto-cel, N=86 SoC). Key baseline characteristics were balanced: 63% of pts were male, median age was 74 y (range 19-87), 85% had DLBCL, 57% were refractory to 1L therapy, 24% relapsed within 12 months and 18% between 1-2years after start of 1L therapy. 57% of patients had IPI 3-5, and 66% were stage III-IV. Of the 82 randomized patients, 76 (93%) received zamto-cel. Six pts did not receive zamto-cel (2× withdrawal, coronary artery stenosis, pneumonia, worsening condition, progressive disease). The median vein-to-vein time was 15 days (range 14-16). At the data cut-off date (15 January 2025) and a median follow-up of 17 months, median EFS was 6.2 months (95% CI 3.8-13.8) for zamto-cel and 2.5 months (95% CI 2.0-3.3) for R-GemOx (HR 0.39; 95% CI 0.27-0.58; p<0.0001). The median PFS was significantly longer with zamto-cel vs R-GemOx (8.5 months [95% CI 3.8-16.8] vs 3.3 months [95% CI 2.0-3.8]; HR 0.43 [95% CI 0.28-0.65]; p<0.0001). In the ITT population, the ORR was 72% (61-81%) with a CR rate of 54% for zamto-cel vs 45% (34-57%) ORR and 14% CR rate for R-GemOx. Among all patients treated with zamto-cel in the experimental arm, the ORR was 78%, with 58% achieving CR. Among patients randomized to SoC, 29 received zamto-cel after crossover. In the zamto-cel arm, CRS Grade (G) ≥ 3 was reported in 4 pts (5.3%; 2 pts G3, 1 pt G4, 1 pt G5). The median time to onset of CRS was 2 days (1-14), median duration was 3 days (1-24). One pt (1.3%) had ICANS G3, no G4/5. For CRS 29 (38%) pts received tocilizumab and 14 (18%) corticosteroids. Persisting neutropenia (≥ 28 days) of G4 was reported in 7 pts (9%). Within 90 days after start of treatment, 8 pts treated with zamto-cel and 8 patients treated with R-GemOx died; the main reason was progression of disease in 4 (50%) and 5 (63%) pts. Conclusions: Zamto-cel demonstrated highly significant and clinically meaningful superiority over R-GemOx in NTE patients at high risk for treatment failure. Moreover, zamto-cel was well tolerated in this vulnerable elderly patient population with low rates of severe CRS and ICANS. This favorable risk/benefit profile suggests the use of zamto-cel as preferred treatment option in 2L for NTE patients with r/r LBCL.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiatian完成签到,获得积分10
刚刚
SciGPT的应助被ldz采纳,获得10
刚刚
1秒前
赖以筠完成签到,获得积分10
1秒前
满君清完成签到,获得积分10
1秒前
斩棘发布了新的文献求助10
1秒前
CodeCraft的应助被躺赢的猴哥采纳,获得10
1秒前
朴素的雪瑶完成签到,获得积分10
1秒前
Quinna完成签到 ,获得积分10
2秒前
英吉利25发布了新的文献求助10
2秒前
赤练仙子发布了新的文献求助30
2秒前
隐形曼青的应助被ctttt采纳,获得10
2秒前
微笑芯完成签到 ,获得积分10
2秒前
海棠未眠完成签到,获得积分10
3秒前
小桃子完成签到,获得积分10
3秒前
清辉夜凝完成签到 ,获得积分10
3秒前
哈拉少发布了新的文献求助10
4秒前
zy完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
科研蜗牛发布了新的文献求助10
4秒前
彤彤完成签到,获得积分10
5秒前
CaliU完成签到,获得积分10
5秒前
5秒前
六六发布了新的文献求助10
6秒前
VVTTWW完成签到 ,获得积分10
6秒前
Zongxin完成签到,获得积分10
6秒前
6秒前
6秒前
里予发布了新的文献求助10
6秒前
shang完成签到,获得积分10
7秒前
球球尧伞耳完成签到,获得积分10
7秒前
dada完成签到,获得积分10
8秒前
8秒前
六六六大瓶完成签到,获得积分10
8秒前
天天向上的应助被隐形的觅云采纳,获得10
8秒前
9秒前
Ava的应助被子车甫昭采纳,获得10
9秒前
臭小子完成签到 ,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105